Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA-KAI study of Moderna COVID-19 vaccination responses in immunocompromised hematology patients
NL-OMON51241Completed
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Vrije University Medical Center. Primary endpoint: Humoral response against SARS-CoV-2 spike antigen. Started Mar 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51241.